english.prescrire.org

Welcome to the Prescrire in English website

Reliable, rigorously independent information on treatments and healthcare strategies,
to enable fully informed decision-making. Prescrire is financed by its subscribers.
No grants, no advertising. No shareholders, no sponsors.

In Prescrire's Spotlight

Hepatitis C treatment with dasabuvir (Exviera°) and the ombitasvir + paritaprevir + ritonavir combination (Viekirax°): await further trials

1 May 2016

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
In the May issue of Prescrire International: Ranibizumab or bevacizumab in AMD?

1 May 2016

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Hypertension: avoid olmesartan pending its withdrawal

1 May 2016

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
New drugs and indications in 2015: little progress, despite exorbitant prices

1 May 2016

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Drug-related hair loss: not only anti-cancer medication

1 May 2016

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Heavy lobbying by pharmaceutical companies in Europe

1 May 2016

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Receive the free, monthly "Independent Drug & Healthcare Newsletter"

1 September 2015

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Subscribe online for full access to content from Prescrire International

1 September 2015